In short
Clinical trials are studying Avacincaptad Pegol in people with geographic atrophy. These studies mainly look at long-term safety and other research outcomes in patients who completed earlier trial treatment. The data here come from a Phase 3 extension study.
Key points
- Clinical trial data for Avacincaptad Pegol show one Phase 3 study in people with geographic atrophy. This trial was an open-label extension study, meaning it followed patients from an earlier study and both patients and researchers knew the treatment. The main goal was to assess long-term safety of monthly intravitreal treatment. The study enrolled 280 participants and was completed. The main endpoint was adverse events, which are unwanted medical problems that happen during a study.
Trial overview
This article covers one clinical trial of Avacincaptad Pegol in people with geographic atrophy. The study was titled “An Open-Label Extension Study for Patients who Previously Completed Study ISEE2008 (GATHER2).” It was a completed Phase 3 interventional trial with 280 participants.
Who participated
The trial focused on patients with geographic atrophy, which is the condition listed in the study record. It included people who had already completed Study ISEE2008 (GATHER2) through the Month 24 visit while on study treatment, either Avacincaptad pegol or Sham. This means the study was a follow-up for patients already involved in earlier research.
Study design and phase
This was an open-label extension study, which means it continued research after the earlier trial and did not hide the treatment assignment from patients or researchers. The study was in Phase 3, a later stage of clinical testing that usually helps researchers collect more safety and outcome data in a larger group of patients. The trial was completed.
What was measured
The main outcome was AEs, short for adverse events. Adverse events are any unwanted medical problems that happen during a study, whether or not they are caused by the study treatment. The stated goal was to assess the long-term safety of monthly intravitreal administration of Avacincaptad pegol in patients with GA who had completed the earlier study.
Key points for patients
This trial was not a first-time study of Avacincaptad Pegol. Instead, it followed patients from an earlier study to learn more about safety over a longer time. The record also lists fluorescein as an intervention, but the main study focus was the safety follow-up of Avacincaptad pegol in geographic atrophy.